Stockwatch: The Pfizer Sanction
This article was originally published in Scrip
Executive Summary
If you are an AstraZeneca shareholder holding your breath since the expiry on 26 August of the three-month ban imposed by the Takeover Panel on Pfizer and AstraZeneca talking to each other about their previously rejected merger, you will have turned blue by now.